Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Plans Boniva Ad Changes To Energize “Static” Script Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss drug maker’s new strategy for the osteoporosis therapy will include Fosamax comparison data, new spokesperson.

You may also be interested in...

Roche/GSK Once-Quarterly Boniva Injection Approved

Injectable ibandronate could improve patient compliance with osteoporosis therapy because it is administered by a healthcare professional, firms say.

Boniva Ad Campaign Prompts Procter & Gamble/Sanofi-Aventis Suit

Procter & Gamble/Sanofi-Aventis allege that Roche and GSK's campaign for Boniva is misleading because it fails to state that Boniva is not approved for treatment of nonspinal fractures.

Roche/GSK Boniva Once-Monthly To Be Launched In April

The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts